市場調査レポート

商品コード

1604459

膵臓がん治療市場：がんタイプ別、治療タイプ別、エンドユーザー別、地域別、機会、予測、2017年～2031年

Pancreatic Cancer Treatment Market Assessment, By Cancer Type, By Treatment Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年12月04日
発行: Market Xcel - Markets and Data
ページ情報: 英文 247 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,500 661,455円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 837,843円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,205,318円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.99円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の膵臓がん治療の市場規模は、予測期間の2024年～2031年に14.40％のCAGRで拡大し、2023年の25億2,000万米ドルから2031年には73億9,000万米ドルに成長すると予測されています。同市場の成長は、膵臓がん患者の増加、主要ヘルスケア企業による研究開発活動への投資の増加、主要製薬企業による医薬品開発努力の高まりによって後押しされています。膵臓がんの有病率の増加は、肥満、飲酒、不健康なライフスタイル、遺伝的要因など様々な要因に起因しています。

世界の膵臓がん治療市場の急速な拡大は、膵臓がんを管理するための効果的な治療オプションに対する要求の高まり、治療技術の進歩、膵臓がんに対する意識の高まりにも起因しています。膵臓がんの死亡率の高さは、症状の発見が限られていることや診断が末期であることに起因しているため、革新的で効果的な治療法が急務となっています。

さらに、主要企業や製薬会社は、潜在的ながんの画期的治療法の開拓に多額の投資を行っており、世界の膵臓がん治療市場に有利な成長機会をもたらしています。過去1年間で、Eli Lilly and Company、AstraZeneca PLC、Bristol-Myers Squibb Companyは、放射性医薬品の提携や共同研究に約100億米ドルを費やしています。製薬会社は、放射線を腫瘍に直接照射することががん治療における次のブレークスルーになると考えています。

放射性医薬品は、がん細胞上の特定のバイオマーカーを検索し、それに付着する標的分子を放射性物質で付着させることで機能します。同様に、2023年12月、Novartis AGは中国の放射性医薬品施設に約8,500万米ドル（6億元）を投資しました。現在、同社は前立腺がんや消化管膵神経内分泌腫瘍にとどまらず、肺がん、大腸がん、乳がん、膵臓がんなどを視野に入れ、新たな併用療法、リガンド、アイソトープを模索しています。計画中の能力拡張に向けた投資は、パイプライン開発の強化、既存ポートフォリオの強化、上市準備、新規治療薬の生産加速につながると期待されています。

当レポートでは、世界の膵臓がん治療市場について調査し、市場の概要とともに、がんタイプ別、治療タイプ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

市場リーダートップ5の競合マトリックス
参入企業トップ5のSWOT分析
市場参入企業トップ10の情勢
- AstraZeneca PLC
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Sanofi S.A.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Takeda Pharmaceutical Company Limited

第21章戦略的提言

第22章お問い合わせと免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 3. Global Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 4. Global Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 5. Global Pancreatic Cancer Treatment Market Share (%), By Region, 2017-2031F
Figure 6. North America Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 7. North America Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 8. North America Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 9. North America Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 10. North America Pancreatic Cancer Treatment Market Share (%), By Country, 2017-2031F
Figure 11. United States Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 12. United States Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 13. United States Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 14. United States Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 15. Canada Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 16. Canada Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 17. Canada Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 18. Canada Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 19. Mexico Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 20. Mexico Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 21. Mexico Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 22. Mexico Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 23. Europe Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 24. Europe Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 25. Europe Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 26. Europe Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 27. Europe Pancreatic Cancer Treatment Market Share (%), By Country, 2017-2031F
Figure 28. Germany Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 29. Germany Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 30. Germany Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 31. Germany Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 32. France Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 33. France Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 34. France Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 35. France Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 36. Italy Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 37. Italy Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 38. Italy Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 39. Italy Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 40. United Kingdom Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 41. United Kingdom Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 42. United Kingdom Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 43. United Kingdom Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 44. Russia Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 45. Russia Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 46. Russia Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 47. Russia Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 48. Netherlands Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 49. Netherlands Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 50. Netherlands Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 51. Netherlands Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 52. Spain Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 53. Spain Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 54. Spain Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 55. Spain Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 56. Turkey Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 57. Turkey Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 58. Turkey Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 59. Turkey Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 60. Poland Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 61. Poland Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 62. Poland Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 63. Poland Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 64. South America Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 65. South America Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 66. South America Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 67. South America Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 68. South America Pancreatic Cancer Treatment Market Share (%), By Country, 2017-2031F
Figure 69. Brazil Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 70. Brazil Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 71. Brazil Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 72. Brazil Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 73. Argentina Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 74. Argentina Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 75. Argentina Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 76. Argentina Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 77. Asia-Pacific Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 78. Asia-Pacific Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 79. Asia-Pacific Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 80. Asia-Pacific Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 81. Asia-Pacific Pancreatic Cancer Treatment Market Share (%), By Country, 2017-2031F
Figure 82. India Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 83. India Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 84. India Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 85. India Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 86. China Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 87. China Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 88. China Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 89. China Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 90. Japan Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 91. Japan Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 92. Japan Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 93. Japan Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 94. Australia Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 95. Australia Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 96. Australia Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 97. Australia Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 98. Vietnam Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 99. Vietnam Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 100. Vietnam Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 101. Vietnam Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 102. South Korea Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 103. South Korea Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 104. South Korea Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 105. South Korea Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 106. Indonesia Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 107. Indonesia Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 108. Indonesia Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 109. Indonesia Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 110. Philippines Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 111. Philippines Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 112. Philippines Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 113. Philippines Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 114. Middle East & Africa Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 115. Middle East & Africa Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 116. Middle East & Africa Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 117. Middle East & Africa Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 118. Middle East & Africa Pancreatic Cancer Treatment Market Share (%), By Country, 2017-2031F
Figure 119. Saudi Arabia Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 120. Saudi Arabia Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 121. Saudi Arabia Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 122. Saudi Arabia Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 123. UAE Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 124. UAE Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 125. UAE Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 126. UAE Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 127. South Africa Pancreatic Cancer Treatment Market, By Value, In USD Billion, 2017-2031F
Figure 128. South Africa Pancreatic Cancer Treatment Market Share (%), By Cancer Type, 2017-2031F
Figure 129. South Africa Pancreatic Cancer Treatment Market Share (%), By Treatment Type, 2017-2031F
Figure 130. South Africa Pancreatic Cancer Treatment Market Share (%), By End-user, 2017-2031F
Figure 131. By Cancer Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 132. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 133. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX12328

Global pancreatic cancer treatment market is projected to witness a CAGR of 14.40% during the forecast period 2024-2031, growing from USD 2.52 billion in 2023 to USD 7.39 billion in 2031. The market's growth is bolstered by the rising cases of pancreatic cancer, increasing investments in research and development activities by leading healthcare organizations, and growing drug development efforts by leading pharmaceutical companies. The increasing prevalence of pancreatic cancer can be attributed to various factors, including obesity, alcohol consumption, unhealthy lifestyle, and genetic factors, among others.

The rapid expansion of the global pancreatic cancer treatment market can also be attributed to the rising requirement for effective therapeutic options for managing pancreatic cancer, advancements in treatment technologies, and rising awareness about the condition. The limited symptom detection and late-stage diagnosis of the condition contribute to the high mortality rate of pancreatic cancer, thus creating an urgent requirement for innovative and effective treatments.

Additionally, leading market players and pharmaceutical companies are significantly investing in developing potential cancer breakthroughs, providing lucrative growth opportunities to the global pancreatic cancer treatment market. Over the past year, Eli Lilly and Company, AstraZeneca PLC, and Bristol-Myers Squibb Company have spent approximately USD 10 billion on radiopharmaceutical partnerships and collaborations. Pharmaceutical companies believe that delivering radiation directly to tumors will be the next breakthrough in cancer treatment. Radiopharmaceuticals work by attaching the targeting molecules that search and attach to specific biomarkers on the cancer cells with the radioactive material. Similarly, in December 2023, Novartis AG invested approximately USD 85 million (600 million yuan) in a radioligand facility in China. Currently, the company is exploring new combination therapies, ligands, and isotopes to look beyond prostate cancer and gastroenteropancreatic neuroendocrine tumors and into lung, colon, breast, and pancreatic cancer. The investment towards the planned capacity expansion is expected to bolster pipeline development, strengthen the existing portfolio, prepare for launches, and accelerate the production of novel therapies.

Rising Prevalence of Pancreatic Cancer Boosts Market Demand

The growing burden of the condition in different regions across the globe is one of the major factors bolstering the global pancreatic cancer treatment market demand. With the increasing prevalence of risk factors for pancreatic cancer across the globe, the cases of pancreatic cancer continue to rise, augmenting the requirement for effective therapeutic solutions. As per the estimates of the World Cancer Research Fund International, in 2022, there were more than 510,992 new cases of pancreatic cancer across the globe. Pancreatic cancer has a high mortality rate; because of this, healthcare systems worldwide are focusing on addressing the condition, and the development of effective therapeutic solutions for the disease is becoming a priority.

Increasing Investments in Research Activities Support Market Expansion

The rising investments in research activities in different research institutions across the globe to support the development of therapies for treating pancreatic cancer are expected to influence the market's expansion positively. Investments towards research and development activities are rapidly increasing to address the unmet requirements of pancreatic cancer, with a wide range of research organizations focusing on combination treatments and innovative therapies. Additionally, a significant increase in explore clinical trials exploring new drug candidates with the potential to improve patient outcomes, including immunotherapies and targeted therapies, are being witnessed, further supporting the market's expansion. Moreover, various non-profit and government organizations are also actively funding new therapies for pancreatic cancer. In May 2024, Walter and Eliza Hall Institute of Medical Research received a USD 8 million investment to create a dedicated research center and spearhead new treatments for pancreatic cancer in Australia. The Hemstritch Centre of Excellence for Pancreatic Cancer Research will provide a leading team of clinicians and scientists with funding to make progress in pancreatic cancer treatments, considered the second deadliest cancer in Australia. Such investments are expected to support the development of the next generation of therapies and provide lucrative growth opportunities for the market.

Chemotherapy Accounts for Significant Market Share

The growth of the segment can be attributed to the rising cases of pancreatic cancer, as chemotherapy is used as the first line of treatment for the condition. Cases of pancreatic cancer are usually diagnosed at an advanced stage, where treatments are limited, and chemotherapy is the primary treatment option available for the management of symptoms and controlling the progression of the disease. Although pancreatic cancer is often unresponsive to various treatments, several chemotherapies have been shown to prolong survival and slow down disease progression.

In September 2024, Silexion Therapeutics announced the results from the phase 2 PROTACT trial (NCT01676259). The trial showed that adding siG12D LODER to the standard-of-care chemotherapy improved overall survival and generated responses compared to chemotherapy alone in patients with KRAS G12D/V mutations.

Meanwhile, radiation therapy is expected to grow significantly over the forecast period. In August 2023, researchers from the University of Texas MD Anderson Cancer Center published their multicenter EXTEND trial findings. The results demonstrated that the addition of metastasis-directed radiation therapy to standard chemotherapy improves progression-free survival in patients suffering from oligometastatic pancreatic cancer. The addition of targeted radiation therapy increased the average progression-free survival by four times, showcasing the paradigm-shifting approach of the treatment for metastatic pancreatic cancer.

North America Holds Major Market Share of the Global Market

The rising cases of pancreatic cancer in the region, coupled with the strong presence of leading pharmaceutical companies and robust healthcare infrastructure, are propelling the growth of the North American pancreatic cancer treatment market. As per the estimates of the American Cancer Society, approximately 66,440 cases of pancreatic cancer are projected to be diagnosed in the United States in 2024. Additionally, the availability of government health insurance such as Medicaid and Medicare for qualifying individuals in the country increases the accessibility of the patient population suffering from chronic conditions, including pancreatic cancer, to various treatment options, further bolstering the market's demand in the region. Moreover, the presence of various organizations, such as the National Pancreatic Cancer Foundation (NPCF), that provide information to patients about medical providers and hospitals in their area along with additional assistance, including counseling, are also supporting the market's expansion. Furthermore, the easy availability of novel therapies and the high acceptance of novel treatment technologies in countries such as Canada and the United States are also positively influencing the expansion of the pancreatic cancer treatment market in the region.

Future Market Scenario (2024-2031F)

As per the global pancreatic cancer treatment market analysis, the market is expected to witness significant growth over the forecast period owing to the rising cases of pancreatic cancer and increasing investments by leading pharmaceutical companies toward the development and production of developing and producing novel therapeutic agents. As per the estimates of an article published in the World Journal of Gastroenterology, in 2050, pancreatic cancer incidences are estimated to increase to 18.6 per 100,000.

The major MedTech and biotech companies are also developing advanced diagnostic solutions to allow early-stage detection of pancreatic cancer, further augmenting the requirement for pancreatic cancer treatments. Advancements in immunotherapy, increasing research and development activities, and growing preference for targeted therapies are also expected to shape the market's landscape. Meanwhile, leading pharmaceutical companies across the globe are continuously working on assessing the safety and efficacy of a wide range of therapies for treating pancreatic cancer. For instance, Ono Pharmaceutical Co., Ltd. is conducting an interventional study to investigate the safety and tolerability of ONO-4538 and ONO-7913 in combination with modified FOLFIRINOX as a first-line treatment for metastatic pancreatic cancer. The study is expected to conclude in May 2025.

Key Players Landscape and Outlook

The key players in the market are actively investing in mergers and acquisitions to advance the development of pharmaceuticals for treating various cancer types. In May 2024, Mariana Oncology, Inc. (Mariana Oncology), a biotechnology company focusing on the innovation of radiopharmaceuticals for treating cancer patients, announced that they have been acquired by Novartis AG (Novartis) for up to USD 750 million in potential milestone payments and USD 1 billion upfront. This acquisition brings together Novartis's commercialization expertise and Mariana Oncology's innovative radiopharmaceutical pipeline, aiding the companies in transforming cancer care. This acquisition is also expected to provide Novartis with new capabilities in radioligand therapeutic research and complement their internal drug discovery and research efforts.

The leading market players are also working on introducing novel drugs for addressing the growing threat of pancreatic cancer. The continuous efforts of pharmaceutical companies across the globe to bolster the availability of treatment options for patients with pancreatic cancer are also supporting the market's expansion, with various drugs receiving approvals from different regulatory bodies. In February 2024, Ipsen Biopharmaceuticals, Inc.'s irinotecan liposome (Onivyde) with leucovorin, oxaliplatin, and fluorouracil was approved by the FDA as first-line treatment for metastatic pancreatic adenocarcinoma. The approval was supported by the results of NAPOLI 3, an open-label, randomized, active-controlled, and multicenter trial.

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Pancreatic Cancer Treatment Market Outlook, 2017-2031F

4.1. Market Size Analysis & Forecast
- 4.1.1. By Value
4.2. Market Share Analysis & Forecast
- 4.2.1. By Cancer Type
  - 4.2.1.1. Endocrine Pancreatic Cancer
  - 4.2.1.2. Exocrine Pancreatic Cancer
- 4.2.2. By Treatment Type
  - 4.2.2.1. Chemotherapy
  - 4.2.2.2. Radiation Therapy
  - 4.2.2.3. Targeted Therapy
  - 4.2.2.4. Immunotherapy
  - 4.2.2.5. Hormone Therapy
  - 4.2.2.6. Others
- 4.2.3. By End-user
  - 4.2.3.1. Hospitals
  - 4.2.3.2. Clinics
  - 4.2.3.3. Cancer Care Centers
  - 4.2.3.4. Others
- 4.2.4. By Region
  - 4.2.4.1. North America
  - 4.2.4.2. Europe
  - 4.2.4.3. Asia-Pacific
  - 4.2.4.4. South America
  - 4.2.4.5. Middle East and Africa
- 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
4.3. Market Map Analysis, 2023
- 4.3.1. By Cancer Type
- 4.3.2. By Treatment Type
- 4.3.3. By End-user
- 4.3.4. By Region

5. North America Pancreatic Cancer Treatment Market Outlook, 2017-2031F*

5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
5.2. Market Share Analysis & Forecast
- 5.2.1. By Cancer Type
  - 5.2.1.1. Endocrine Pancreatic Cancer
  - 5.2.1.2. Exocrine Pancreatic Cancer
- 5.2.2. By Treatment Type
  - 5.2.2.1. Chemotherapy
  - 5.2.2.2. Radiation Therapy
  - 5.2.2.3. Targeted Therapy
  - 5.2.2.4. Immunotherapy
  - 5.2.2.5. Hormone Therapy
  - 5.2.2.6. Others
- 5.2.3. By End-user
  - 5.2.3.1. Hospitals
  - 5.2.3.2. Clinics
  - 5.2.3.3. Cancer Care Centers
  - 5.2.3.4. Others
- 5.2.4. By Country Share
  - 5.2.4.1. United States
  - 5.2.4.2. Canada
  - 5.2.4.3. Mexico
5.3. Country Market Assessment
- 5.3.1. United States Pancreatic Cancer Treatment Market Outlook, 2017-2031F*
  - 5.3.1.1. Market Size Analysis & Forecast
    - 5.3.1.1.1. By Value
  - 5.3.1.2. Market Share Analysis & Forecast
    - 5.3.1.2.1. By Cancer Type
      - 5.3.1.2.1.1. Endocrine Pancreatic Cancer
      - 5.3.1.2.1.2. Exocrine Pancreatic Cancer
    - 5.3.1.2.2. By Treatment Type
      - 5.3.1.2.2.1. Chemotherapy
      - 5.3.1.2.2.2. Radiation Therapy
      - 5.3.1.2.2.3. Targeted Therapy
      - 5.3.1.2.2.4. Immunotherapy
      - 5.3.1.2.2.5. Hormone Therapy
      - 5.3.1.2.2.6. Others
    - 5.3.1.2.3. By End-user
      - 5.3.1.2.3.1. Hospitals
      - 5.3.1.2.3.2. Clinics
      - 5.3.1.2.3.3. Cancer Care Centers
      - 5.3.1.2.3.4. Others
- 5.3.2. Canada
- 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Pancreatic Cancer Treatment Market Outlook, 2017-2031F

6.1. Germany
6.2. France
6.3. Italy
6.4. United Kingdom
6.5. Russia
6.6. Netherlands
6.7. Spain
6.8. Poland

7. Asia-Pacific Pancreatic Cancer Treatment Market Outlook, 2017-2031F

7.1. India
7.2. China
7.3. Japan
7.4. Australia
7.5. Vietnam
7.6. South Korea
7.7. Indonesia
7.8. Philippines

8. South America Pancreatic Cancer Treatment Market Outlook, 2017-2031F

8.1. Brazil
8.2. Argentina

9. Middle East and Africa Pancreatic Cancer Treatment Market Outlook, 2017-2031F

9.1. Saudi Arabia
9.2. UAE
9.3. South Africa
9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

15.1. Market Drivers
15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

17.1. Clinical Trials
17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

20.1. Competition Matrix of Top 5 Market Leaders
20.2. SWOT Analysis for Top 5 Players
20.3. Key Players Landscape for Top 10 Market Players
- 20.3.1. AstraZeneca PLC
  - 20.3.1.1. Company Details
  - 20.3.1.2. Key Management Personnel
  - 20.3.1.3. Products and Services
  - 20.3.1.4. Financials (As Reported)
  - 20.3.1.5. Key Market Focus and Geographical Presence
  - 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
- 20.3.2. Pfizer Inc.
- 20.3.3. Teva Pharmaceutical Industries Ltd.
- 20.3.4. Novartis AG
- 20.3.5. Sanofi S.A.
- 20.3.6. GlaxoSmithKline plc
- 20.3.7. Merck & Co., Inc.
- 20.3.8. Bristol-Myers Squibb Company
- 20.3.9. Eli Lilly and Company
- 20.3.10. Takeda Pharmaceutical Company Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

膵臓がん治療市場：がんタイプ別、治療タイプ別、エンドユーザー別、地域別、機会、予測、2017年～2031年

Pancreatic Cancer Treatment Market Assessment, By Cancer Type, By Treatment Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の膵臓がん治療市場の見通し、2017年～2031年

第5章 北米の膵臓がん治療市場の見通し、2017年～2031年

第6章 欧州の膵臓がん治療市場の見通し、2017年～2031年

第7章 アジア太平洋の膵臓がん治療市場の見通し、2017年～2031年

第8章 南米の膵臓がん治療市場の見通し、2017年～2031年

第9章 中東・アフリカの膵臓がん治療市場の見通し、2017年～2031年

第10章 需要供給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

第16章 市場の動向と発展

第17章 規制枠組みとイノベーション

第18章 特許の情勢

第19章 ケーススタディ

第20章 競合情勢

第21章 戦略的提言

第22章 お問い合わせと免責事項

List of Tables

List of Figures

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Pancreatic Cancer Treatment Market Outlook, 2017-2031F

5. North America Pancreatic Cancer Treatment Market Outlook, 2017-2031F*

6. Europe Pancreatic Cancer Treatment Market Outlook, 2017-2031F

7. Asia-Pacific Pancreatic Cancer Treatment Market Outlook, 2017-2031F

8. South America Pancreatic Cancer Treatment Market Outlook, 2017-2031F

9. Middle East and Africa Pancreatic Cancer Treatment Market Outlook, 2017-2031F

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

16. Market Trends and Developments

17. Regulatory Framework and Innovation

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

21. Strategic Recommendations

22. About Us and Disclaimer

第1章プロジェクトの範囲と定義

第2章調査手法

第3章エグゼクティブサマリー

第4章世界の膵臓がん治療市場の見通し、2017年～2031年

第5章北米の膵臓がん治療市場の見通し、2017年～2031年

第6章欧州の膵臓がん治療市場の見通し、2017年～2031年

第7章アジア太平洋の膵臓がん治療市場の見通し、2017年～2031年

第8章南米の膵臓がん治療市場の見通し、2017年～2031年

第9章中東・アフリカの膵臓がん治療市場の見通し、2017年～2031年

第10章需要供給分析

第11章バリューチェーン分析

第12章ポーターのファイブフォース分析

第14章価格分析

第15章市場力学

第16章市場の動向と発展

第17章規制枠組みとイノベーション

第18章特許の情勢

第19章ケーススタディ

第20章競合情勢

第21章戦略的提言

第22章お問い合わせと免責事項